ArticleCell reports. Medicine2024

Glycoengineering-based anti-PD-1-iRGD peptide conjugate boosts antitumor efficacy through T cell engagement.

Yunfeng Pan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.